The Centers for Medicare & Medicaid Services intends to test whether phasing down the Medicare payment amount for selected Part B drugs to more closely align with international prices will meet President Trump’s blueprint to lower drug costs and reduce out-of-pocket costs for patients. CMS is soliciting public comments by